Edimer Pharmaceuticals and CMC Biologics Announce Agreement to Manufacture EDI200 Recombinant Protein

CAMBRIDGE, Massachusetts and BOTHELL, Washington, September 9, 2010 - Edimer Pharmaceuticals and CMC Biologics today announce the execution of
a manufacturing contract to support the development of EDI200, a
clinical-stage recombinant protein for the treatment of X-linked Hypohidrotic
Ectodermal Dysplasia (XLHED), a rare genetic disease with orphan designation
in the USA and Europe.

    (Logo: photos.prnewswire.com/prnh/20100909/SF59797LOGO)
    (Logo: www.newscom.com/cgi-bin/prnh/20100909/SF59797LOGO)

    (Logo: photos.prnewswire.com/prnh/20100824/SF54816LOGO)
    (Logo: www.newscom.com/cgi-bin/prnh/20100824/SF54816LOGO)

CMC Biologics was selected by Edimer for their lead product due to its
depth of expertise in protein development, analytical development and its
cGMP manufacturing capabilities.

Neil Kirby, Ph.D., Edimer CEO, commented, "CMC's extensive experience in
the GMP manufacture of therapeutic proteins makes them an ideal company to
help us move this product forward. We believe that this product has the
potential for making a difference in individuals' lives that currently have
no available therapeutic options."

Gustavo Mahler, Ph.D., CMC Biologics Chief Operating Officer noted, "CMC
is delighted to be able to assist Edimer in the development and production of
this orphan protein. Our two teams are working together in an open and
collaborative manner and we are excited about the project's potential."

About EDI200

Ectodysplasin-A1 (EDA-A1) is a signaling protein expressed in healthy
individuals that is involved in the formation of sweat glands, teeth, hair
and certain glandular structures. This protein is missing in patients with
XLHED. EDI200 is a form of EDA-A1 being developed by Edimer as a treatment
for certain patients with XLHED. EDI200 has been shown to substitute for lack
of functional EDA-A1 protein in mouse and dog models of XLHED.

About Edimer Pharmaceuticals

Edimer Pharmaceuticals (www.edimerpharma.com)

Edimer is dedicated to deliver a significant and durable improvement in
the health and quality of life to future generations affected by XLHED.
Edimer was established in 2009 based on research conducted at the University
of Lausanne, Switzerland. Edimer's lead product candidate, EDI200, represents
the first of a new class of molecules designed to correct a developmental
disorder in a pediatric population.

About CMC

CMC Biologics (www.cmcbio.com) is a leading contract development
and manufacturing organization that provides fully integrated
biopharmaceutical development and manufacturing services to clients around
the world, from its facilities in Copenhagen, Denmark, and Seattle, WA. The
company specializes in custom services for the scale-up and cGMP manufacture
of protein-based therapeutics for pre-clinical, clinical trials and in-market
production. CMC Biologics' wide range of integrated services includes cell
line development using its proprietary CHEF1(R) system, process development
and comprehensive analytical testing. CMC Biologics has fully segregated
microbial fermentation and mammalian cell culture suites and offers both
stirred tank and perfusion production processes.

Jeff Behrens, Senior Director, Business Development & Operations of Edimer Pharmaceuticals, +1-617-758-4300, jeff at edimerpharma.com; or Jenifer L. Wheat, V.P. Business Development of CMC Biologics, +1-425-485-1900, jwheat at cmcbio.com